Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| MD Group | Healthcare Services | 21.5% | 79th pct | 268 |
| MedX | Healthcare Services | 14.2% | 63rd pct | 268 |
| Me-11 Kalta Konsultatsia | Healthcare Services | -5.1% | 18th pct | 268 |
| Tbilisis 25-E Mozrdilta… | Healthcare Services | -7.0% | 16th pct | 268 |
| Lilos Sameditsino Tsent… | Healthcare Services | -12.4% | 13th pct | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | MD Group | MedX | Me-11 Kalta Konsultatsia | Tbilisis 25-E Mozrdilta… | Lilos Sameditsino Tsent… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 83.0% | 92.2% | 97.8% | 100.0% | 100.0% |
| EBITDA Margin | 21.5% | 14.2% | -5.1% | -7.0% | -12.4% |
| EBITDAR | 133 | 74 | -18 | -21 | -23 |
| EBITDAR Margin | 25.9% | 14.9% | -5.1% | -7.0% | -12.4% |
| EBIT Margin | 1.1% | 2.6% | -29.0% | -7.0% | -27.0% |
| Net Profit Margin | -1.8% | -10.8% | -29.1% | -3.3% | 295.7% |
| Operating Expense % of Sales | 61.5% | 78.0% | 102.9% | 107.0% | 112.4% |
| Returns | |||||
| Return on Assets (ROA) | -0.8% | -5.1% | -11.6% | -7.3% | 39.4% |
| Return on Equity (ROE) | -1.8% | -17.9% | -12.8% | -21.8% | 164.7% |
| ROIC [EBIT / Invested Capital] | 0.5% | 1.3% | -13.0% | -46.0% | -15.1% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 50.4% | 71.6% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 1.18x | 2.52x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 5.44x | 10.74x | N/A | N/A | N/A |
| Equity-to-Assets | 42.8% | 28.4% | 90.5% | 33.6% | 23.9% |
| Net Debt | 596 | 703 | -18 | -0 | -1 |
| Cash & Equivalents | 4 | 49 | 18 | 0 | 1 |
| Total Debt | 600 | 752 | N/A | N/A | N/A |
| Liquidity & working capital | |||||
| Current Ratio | 1.47x | N/A | 10.54x | 0.34x | 0.24x |
| Quick Ratio | 1.47x | N/A | 10.54x | 0.34x | 0.24x |
| Cash Ratio | 0.02x | N/A | 0.22x | 0.00x | 0.00x |
| Total Current Assets | 234 | 49 | 875 | 46 | 337 |
| Total Current Liabilities | 159 | N/A | 83 | 137 | 1,410 |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Trade Receivables | 105 | 38 | 21 | N/A | 126 |
| Trade Payables | 58 | N/A | 5 | N/A | 43 |
| Net Working Capital | 74 | 49 | 792 | -91 | -1,073 |
| Net Working Capital % of Revenue | 14.5% | 9.9% | 227.5% | -30.0% | -571.4% |
| Trade Working Capital | 47 | 38 | 17 | N/A | 84 |
| Trade Working Capital % of Revenue | 9.1% | 7.8% | 4.8% | N/A | 44.6% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover | 4.90x | 12.89x | 16.52x | N/A | 1.49x |
| Days Sales Outstanding (DSO) | 74.5 | 28.3 | 22.1 | N/A | 245.6 |
| Payables Turnover | 1.51x | N/A | 1.68x | N/A | N/A |
| Days Payable Outstanding (DPO) | 242.3 | N/A | 216.6 | N/A | N/A |
| Cash Conversion Cycle | -167.8 days | 28.3 days | -194.5 days | N/A | 245.6 days |
| Asset Turnover | 0.43x | 0.47x | 0.40x | 2.21x | 0.13x |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | N/A | -378 | 314 | -1 |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A | -378 | 314 | -1 |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | N/A | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |